In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder &amp; Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/georg-vo-beiske-797a1549/" target="_blank">Georg Vo Beiske</a>, CEO, Tribune Therapeutics<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jonas-hall%C3%A9n-96084a13/" target="_blank">Jonas Hallén</a>, Co-Founder &amp; CMO, Calluna PharmaDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.